BBH
·NASDAQ
--
--(--)
--
--(--)
Key Stats
Assets Under Management
398.63MUSD
Fund Flows (1Y)
-84.97MUSD
Dividend Yield
0.65%
Discount/Premium to NAV
-0.05%
Shares Outstanding
2.08M
Expense Ratio
0.35%
About VanEck Biotech ETF
Issuer
Van Eck Associates Corporation
Brand
VanEck
Inception Date
Dec 20, 2011
Structure
Open-Ended Fund
Index Tracked
MVIS US Listed Biotech 25 Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
Van Eck Associates Corp.
Distributor
Van Eck Securities Corp.
BBH offers a more concentrated take on the global biotech industry. Although the space is already dominated by US firms, the fund aims to select just 25 US listed companies by market cap, also weighing each constituent by market cap. The underlying index has a flexible definition of biotech, encompassing companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment, excluding pharmacies. Also, despite capping its issuers to a maximum of 20%, the fund may still be top heavy due to the index's concentrated nature. Overall, BBH is a viable take on this market. The index is reviewed semi-annually.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Biotechnology
Strategy
Vanilla
Geography
U.S.
Weighting Scheme
Market Cap
Selection Criteria
Market cap
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | +0.97% | +14.57% | +21.95% | +22.29% | +18.70% | +9.90% |
NAV Total Return | +1.80% | +12.48% | +21.35% | +15.71% | +17.59% | +11.56% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region
100%
Category
Ratio
North America
100.00%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Multi-Cap Growth
Comprises companies of multiple sizes that have high growth potential. These ETFs focus on firms across different market caps with promising growth prospects.
Top 10 Holdings
Symbol
Ratio
AMGN
Amgen
13.03%
GILD
Gilead Sciences
11.90%
VRTX
Vertex Pharmaceuticals
9.55%
REGN
Regeneron
5.92%
NTRA
Natera
5.13%
ARGX
argenx
4.88%
IQV
IQVIA
4.79%
INSM
Insmed
4.52%
UTHR
United Therapeutics
3.81%
ONC
Beone Medicines
3.73%
Top 10 Weight 67.26%
27 Total Holdings
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2024-12-23 | 2024-12-23 | 2024-12-24 | 1.252 |
| 2023-12-18 | 2023-12-19 | 2023-12-22 | 0.713 |
| 2022-12-19 | 2022-12-20 | 2022-12-23 | 0.749 |
| 2021-12-20 | 2021-12-21 | 2021-12-27 | 0.397 |
| 2020-12-21 | 2020-12-22 | 2020-12-28 | 0.608 |
| 2019-12-23 | 2019-12-24 | 2019-12-30 | 0.472 |
| 2018-12-20 | 2018-12-21 | 2018-12-27 | 0.551 |
Show more
Premium/Discount Chart
Premium/Discount to NAV
Price
1M
Assets Under Management
Assets Under Management
1M
Fund Flows
Inflows
Outflows
1M
